|
1
|
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
|
Antimicrob Agents Chemother
|
2013
|
1.10
|
|
2
|
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
|
J Med Chem
|
2013
|
0.97
|
|
3
|
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
|
J Med Chem
|
2014
|
0.93
|
|
4
|
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
|
Antimicrob Agents Chemother
|
2012
|
0.93
|
|
5
|
Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis.
|
Antimicrob Agents Chemother
|
2013
|
0.87
|
|
6
|
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
|
J Med Chem
|
2014
|
0.83
|
|
7
|
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
|
J Med Chem
|
2014
|
0.82
|
|
8
|
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
|
J Med Chem
|
2014
|
0.82
|
|
9
|
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
|
J Med Chem
|
2014
|
0.82
|
|
10
|
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
|
J Med Chem
|
2013
|
0.78
|